FibroBiologics (NASDAQ:FBLG) took a decisive step toward clinical-stage operations on Wednesday, filing an Investigational New Drug (IND) application with the U.S. Food and Drug Administration to begin Phase 1/2 trials for its lead psoriasis candidate, CYPS317.
Corcept Therapeutics (NASDAQ:CORT) shares plunged Wednesday after the U.S. Food and Drug Administration (FDA) rejected its New Drug Application (NDA) for relacorilant, a treatment for hypertension caused by excessive cortisol levels.
Axsome Therapeutics (NASDAQ:AXSM) shares edged higher Wednesday after the U.S. Food and Drug Administration (FDA) granted Priority Review to its supplemental New Drug Application (sNDA) for AXS-05, a treatment targeting the pervasive and distressing agitation associated with Alzheimer’s disease.
Axsome Therapeutics (NASDAQ:AXSM) is poised to file for U.S. regulatory approval of its narcolepsy treatment, AXS-12, following a successful pre-New Drug Application (NDA) meeting with the Food and Drug Administration.
MetLife Investment Management (MIM), the institutional asset management arm of MetLife (NYSE:MET), completed its acquisition of PineBridge Investments on Tuesday, creating a combined investment powerhouse with approximately $734.7 billion in assets under management.
AtaiBeckley (NASDAQ:ATAI) has officially completed its redomiciliation from the Netherlands to Delaware, finalizing a corporate overhaul that follows the recent strategic combination of atai Life Sciences and Beckley Psytech.
Vanda Pharmaceuticals (NASDAQ:VNDA) has secured U.S. Food and Drug Administration approval for NEREUS™ (tradipitant), ending a four-decade drought in new pharmacological treatments for motion sickness.
Measles cases in the United States have climbed to their highest level in decades as health officials warn of new exposures and falling vaccination rates.
FTAI Aviation (NASDAQ:FTAI) saw its shares rise by 8.8% in the morning session after announcing the launch of FTAI Power, a new venture aimed at repurposing its CFM56 aircraft engines into 25-megawatt power turbines.
Lexaria Bioscience Corp. (NASDAQ:LEXX) announced positive findings from its Phase 1b clinical study GLP-1-H24-4, a 12-week chronic trial focusing on its DehydraTECH™ (DHT) delivery platform in comparison to the Rybelsus® control arm.
Cycurion closed 2025 with a strong financial position, reporting an $80 million contracted backlog and bolstered liquidity as the company accelerates into 2026.
For the third quarter of 2025, Cycurion, which trades on the Nasdaq under the ticker CYCU, reported revenue of $3.83 million, a 13.9% year-over-year decrease. However, total assets grew to $32.31 million, an increase of 26.4%, and cash reserves rose significantly to $3.65 million, compared to just $0.04 million at the end of 2024.
The company saw net financing inflows of $10.78 million and is forecasting a Q1 2026 run-rate revenue of approximately $4.17 million, which would annualize to around $16.66 million.
Recent business wins include a multi-year telecom deployment with potential revenue exceeding $1 million, a state and local government data modernization project, and a $1.1 million county contract. Cycurion also declared a pro-rata share dividend of $0.0080 per share, payable around December 30, 2025.
Cycurion’s strategic focus on government and commercial sectors continues to drive growth as the company strengthens its foundation for expansion into 2026.
Denali Therapeutics (NASDAQ:DNLI) announced promising Phase 1/2 results for tividenofusp alfa (DNL310) in the treatment of Hunter syndrome, with the data published in The New England Journal of Medicine supporting an FDA Priority Review. The FDA has set a Prescription Drug User Fee Act (PDUFA) date for April 5, 2026.
